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Background: Sebaceous neoplasm is a rare subgroup of ap-
pendageal tumors that differentiate towards sebaceous ad-
nexal structures of the skin and are known to be associated 
with visceral malignancy. Objective: We aimed to analyze 
and compare the clinical data including the past history of as-
sociated visceral malignancy in patients with sebaceous car-
cinoma (SC) and benign sebaceous neoplasms (BSN), such as 
sebaceous adenomas and sebaceomas. Methods: We retro-
spectively reviewed the cases of consecutive patients diag-
nosed with sebaceous neoplasms. Basic demographic data, 
past medical history, and clinical data regarding the size, lo-
cation, and presence of associated visceral malignancies 
were evaluated. Results: A total of 80 patients of sebaceous 
neoplasms (51 SC, 29 BSN) were included. A total of 18 asso-
ciated visceral malignancies were found in 14 patients (8 SC, 
6 BSN). Two patients were diagnosed with subsequent vis-
ceral malignancies during the primary work-up process for 
sebaceous neoplasms. The mean age at diagnosis of the vis-
ceral malignancies was 63.9 and 47.5 years for patients with 
SC and BSN, respectively. The most common site of visceral 
malignancies was the gastrointestinal (GI) tract. Adenocarci-
noma was the most common histologic type of the visceral 
malignancy noted. Conclusion: We observed associated vis-
ceral malignancies in 15.7% of patients with SC and 20.7% 
with BSN. Our results suggest a need for screening of visceral 
malignancies, especially of the GI tract, in patients with seba-
ceous neoplasms. (Ann Dermatol 31(1) 14∼21, 2019)
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INTRODUCTION
Sebaceous neoplasm is a rare subgroup of appendageal tu-
mor that differentiates towards sebaceous adnexal struc-
tures of the skin. Appendageal tumors with sebaceous dif-
ferentiation are widely classified into 3 subgroups accord-
ing to the gradient of decreasing differentiation: (1) hyper-
plasias and hamartomas - nevus sebaceous and sebaceous 
hyperplasia, (2) benign neolplasms - sebaceous adenoma 
and sebaceoma and (3) malignant neoplasms - sebaceous 
carcinoma (SC)1. Sebaceous neoplasms may occur at any 
age but usually affect elderly population. These tumors 
most commonly present on the head and neck, and due to 
their heterogeneous clinical features, are often difficult to 
distinguish from other cutaneous neoplasms such as basal 
cell carcinoma and squamous cell carcinoma. Therefore, 
histopathologic examination is required for definitive diag-
nosis2. Despite advances in understanding the histopatho-
logic features of sebaceous neoplasms, relatively little is 
known about the clinical features of patients with seba-
ceous neoplasms, especially in those with benign seba-
ceous neoplasm (BSN). Additionally, sebaceous adenomas 
are known to be associated with visceral malignancy1, 
However, there are few published studies assessing the 
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clinical features of associated visceral malignancy such as 
the frequency and location in the patients with Muir-Torre 
syndrome (MTS) and there are no previous studies assess-
ing associated visceral malignancy in patients with seba-
ceous neoplasm without MTS. Information regarding asso-
ciated visceral malignancy in patients with sebaceous neo-
plasm would be helpful in the diagnosis of visceral malig-
nancy considering that sebaceous neoplasms are visible 
lesions which can be easily diagnosed with skin biopsy.
Therefore, in this study we examined the basic demo-
graphic data, presenting clinical features and character-
istics of associated visceral malignancies in Korean pa-
tients diagnosed with sebaceous neoplasms.
MATERIALS AND METHODS
Study subjects
This retrospective case review was performed at two ter-
tiary referral-based hospitals, Severance Hospital and 
Gangnam Severance Hospital, affiliated with Yonsei 
University Health System (YUHS). Consecutive patients 
who visited the departments of Dermatology and 
Ophthalmology between June 2007 and May 2017 who 
were histologically diagnosed as SC, sebaceous adenoma 
and sebaceoma were included and their medical records 
from the electronic health record (EHR) system of YUMC 
were reviewed.
Analysis of clinical data
Patients were divided into two groups: the SC group and 
the BSN group, which included sebaceous adenomas and 
sebaceomas. We compared the basic clinical data ob-
tained for all patients between the two groups including 
age, sex, duration, location of the primary tumor, tumor 
size, comorbidity, treatment, recurrence and presence of 
distant metastases. Among the patients with presence of 
associated visceral malignancies, we obtained and com-
pared further additional clinical data including the age at 
diagnosis of visceral malignancies and the number of asso-
ciated visceral malignancies. We received the patient’s 
consent form about publishing all photographic materials.
Statistical analysis
The SC group and the BSN group were compared 
statistically. Statistical analyses were performed using SPSS 
software ver. 23.0 (IBM Co., Armonk, NY, USA). The re-
sults were expressed as means±standard deviations. The 
unpaired t-test was performed for continuous variables. To 
compare the categorical data, the chi-square test or the 
Fisher exact test was used. p-value＜0.05 were considered 
to be statistically significant.
Ethics statement
This study was reviewed and approved by the Institutional 
Review Board of the Gangnam Severance Hospital, 
Yonsei University College of Medicine, Seoul, Korea (IRB 
no. 3-2018-0014) and adhered to the tenets of the 
Declaration of Helsinki.
RESULTS
Patient demographics
A total of 80 patients with sebaceous neoplasms were in-
cluded in this study. Of the 80 patients, 51 were diag-
nosed with SC and 29 with BSN. The detailed demo-
graphic and clinical characteristics are provided in Table 
1. The mean age at diagnosis was 62.6±15.6 (range, 36∼
94) years for patients with SCs and 58.4±14.7 (range, 31∼
87) years for patients with BSNs. The mean age at onset of 
the sebaceous neoplasms was 60.0±18.7 (range, 19∼92) 
years for SC patients and 50.9±18.6 (range, 10∼87) years 
for BSN patients. The mean age at onset was earlier in the 
BSN group than the SC group. In terms of distribution of 
sex, SCs had a female dominant distribution (M:F=1:1.8), 
whereas BSNs did not show gender differences. The most 
frequent location of SCs and BSNs was the head and neck 
area (49/51, 96.1% and 28/29, 96.6% respectively). SCs 
were most frequently located on the eyelids (41/51, 
80.4%), while BSNs did not showed any site predilection. 
In the SC group, 50 patients showed solitary lesions and 
just one patient showed multiple lesions. In the BSN 
group, 4 of 29 patients had multiple lesions. There was no 
difference in the mean size of tumor at diagnosis (SC, 1.4 cm; 
BSN, 1.1 cm). Clinical and histopathologic presentations 
of sebaceous neoplasms are shown in Fig. 1, 2. In the SC 
group, hypertension (11/51, 21.6%) was the most fre-
quently associated comorbidity followed by diabetes mel-
litus (9/51, 17.7%). Associated visceral malignancy was 
observed in 8 patients (15.7%). In the BSN group, visceral 
malignancy was the most frequently associated co-
morbidity (6/29, 20.7%), followed by hypertension (5/29, 
17.2%).
Treatment and prognosis
For the treatment of SCs, 6 patients (11.8%) received 
Mohs micrographic surgery (MMS) and 44 (86.2%) re-
ceived wide local excision (WLE). The final 1 patient re-
ceived radiation therapy due to old age and a poor gen-
eral condition. In the BSN group, 2 patients (6.9%) under-
went MMS and 15 (51.7%) underwent WLE. Five patients 
(17.2%) received cryotherapy or laser therapy and 7 
(24.1%) did not receive any treatment. The mean follow- 
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Table 1. Baseline clinical characteristics of 80 sebaceous 
neoplasm patients
Factors
Sebaceous 
carcinoma
(n=51)
Benign 
sebaceous 
neoplasms
(n=29)
Age at diagnosis (yr) 62.6±15.6 58.4±14.7
Gender 
  Male 18 (35.3) 14 (48.3)
  Female 33 (64.7) 15 (51.7)
Duration (mo) 23.7±39.4 85.7±148.5
Age at onset of SN (yr) 60.0±16.6 50.9±18.6
Location 
  Head and neck 49 (96.1) 28 (96.6)
    Scalp 2 (3.9) 6 (20.7)
    Forehead 1 (2.0) 1 (3.5)
    Temple 0 (0.0) 3 (10.3)
    Eyelid 41 (80.4) 3 (10.3)
    Ear 2 (4.0) 2 (6.9)
    Nose 1 (2.0) 4 (13.8)
    Cheek 1 (2.0) 7 (24.1)
    Philtrum 1 (2.0) 0 (0.0)
    Neck 0 (0.0) 2 (6.9)
  Trunk 2 (3.9) 1 (3.5)
Size (cm) 1.4±1.3 1.1±0.8
Comorbidity 
  Hypertension 11 (21.6) 5 (17.2)
  Diabetes mellitus 9 (17.7) 3 (10.3)
  Coronary artery 
obstructive disease
3 (5.9) 1 (3.5)
  Benign prostatic 
hyperplasia
1 (2.0) 3 (10.3)
  Tubular adenoma 1 (2.0) 4 (13.8)
  Visceral malignancy 8 (15.7) 6 (20.7)
Treatment 
  Mohs micrographic 
surgery
6 (11.8) 2 (6.9)
  Wide local excision 44 (86.2) 15 (51.7)
  Radiotherapy 1 (2.0) 0 (0.0)
  Cryotherapy 0 (0.0) 2 (6.9)
  Laser 0 (0.0) 3 (10.3)
  None 0 (0.0) 7 (24.1)
Recurrence 4 (7.7) 1 (3.5)
  Local recurrence 1 (2.0) 1 (2.0)
  Distant metastases 3 (5.9) 0 (0.0)
Follow-up period (mo) 27.9±26.3 18.3±34.0
Values are presented as mean±standard deviation or number 
(%). SN: sebaceous neoplasm. 
up period was 27.9±26.3 months for SC patients and 
18.3±34.0 months for BSN patients and there was no sig-
nificant difference between the two groups. During the 
follow-up period, recurrence was observed in 4 SC pa-
tients: 1 had a local recurrence while the other 3 patients 
showed distant metastasis to the lung, parotid gland and 
neck lymph nodes. The mean duration to recurrence was 
13.25±5.6 (range, 7∼20) months. Among the BSN group, 
1 patient who was treated with ablative CO2 laser showed 
local recurrence.
Sebaceous neoplasms and visceral malignancies
The clinical data of patients with associated visceral malig-
nancies are shown in Table 2 and Table 3. A total of 14 
patients (17.5%) had associated visceral malignancy; 8/51 
patients (15.7%) were in the SC group and 6/29 (20.7%) 
with in the BSN. In the SC group, patients were found to 
have only one visceral malignancy. Interestingly, among 
the 6 patients with BSNs, 3/6 patients (50.0%) were asso-
ciated with multiple visceral malignancies, while the other 
3 patients had 1 visceral malignancy: among those with 
multiple malignancies, 1 patient had 3 and 2 patients 
were found to have 2 visceral malignancies. Over all, in 
this subset of patients with confirmed visceral malignancy, 
the mean age at diagnosis of the sebaceous neoplasms 
was 68.1±10.9 (range, 46∼82) years for SC patients and 
53.7±4.8 (range, 46∼59) years for BSN patients. The 
mean age at diagnosis of the visceral malignancies was 
63.9±10.3 (range, 47∼79) years for SC patients and 
47.5±5.7 (range, 41∼55) years for BSN patients. The di-
agnosis of sebaceous neoplasms preceded that of visceral 
malignancy by 4.2 and 6.4 years in SC and BSN patients, 
respectively. Two patients with SC were diagnosed with a 
subsequent visceral malignancy during the process of 
work-up.
A total of 18 visceral malignancies were found in 14 pa-
tients, 8 in the SC group and 10 in the BSN group. The de-
tailed characteristics of the associated visceral malig-
nancies can be seen in Table 4. Among the 18 visceral 
malignancies, the most common site was the gastro-
intestinal (GI) tract (9/18, 50.0%). In particular, we found 
4 GI tract cancers that were associated with BSN and all 
were diagnosed as colon or rectal cancers. The other sites 
involved were the bile duct, thyroid, breast, ureter, pros-
tate and uterus. The histologic type of visceral malig-
nancies was described in 13 visceral malignancies, and all 
were adenocarcinoma (13/18, 72.2%).
DISCUSSION
Sebaceous neoplasms are widely classified into 3 types of 
tumors; SC, sebaceous adenomas and sebaceomas. SC is a 
rare malignant neoplasm of the sebaceous glands, com-
monly diagnosed in older adults and with no known gen-
der predilections3. SC is divided into extraocular and ocu-
lar types according to the location of the tumor. The ocu-
lar type, which is located on the periorbital area, account 
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Fig. 2. Histopathologic presentations
of sebaceous neoplasms. (A, B) 
Sebaceous carcinoma. (A) Multilo-
bular basaloid tumors are associated
with epidermal ulceration (H&E, 
×40). (B) The constituent cells, both
basaloid cells and sebocytes, dem-
onstrate marked cytologic atypia 
and mitotic activity (H&E, ×400).
(C, D) Benign sebaceous neoplasms.
The tumor is composed of enlarged 
sebaceous lobules with two types 
of mature cells: sebaceous and ba-
saloid cells (H&E, ×100). (C) Seba-
ceous cells predominate in seba-
ceous adenoma and (D) basaloid 
cells in sebaceoma (H&E, ×100).
Fig. 1. Clinical presentations of se-
baceous neoplasms. (A) Extraocular 
sebaceous carcinoma presenting as 
a crusted yellowish nodule with 
erythematous base on the neck. (B) 
Sebaceous adenoma presenting as 
an erythematous nodule with central
umbilication on the left cheek.
for 75% of SC3. Typically, SC presents as a pink or yellow 
nodule or plaque. BSN includes sebaceous adenoma and 
sebaceoma. Sebaceous adenomas typically presents as 
solitary or multiple nodules less than 1 cm in size with 
tan, pink or yellow coloring. The clinical presentation of 
sebaceoma is not distinct, with appearance of papular, 
nodular, keratotic or ulcerated lesions. These two neo-
plasms are distinguished with histological features. 
Sebaceoma is diagnosed when it is composed with greater 
than 50% of germinative basaloid cells. Otherwise the di-
agnosis of sebaceous adenoma can be made3. In this 
study, we sought to assess the clinical features of patients 
with SC and BSN. We also evaluated the incidence and 
clinical characteristics of associated visceral malignancies. 
In our study, the mean age at diagnosis was 62.6 years, 
which was at a younger age compared with previously 
published studies. Additionally, our results showed a fe-
male predilection (64.7%). The ocular type occupied 
80.4% of the total SC, which was similar to previously 
published data. The differences in these results may be 
due to several factors. First, our data is based on the 
Korean population. According to Park et al.’s report4, 
which analyzed the clinicopathologic data of Korean SC 
patients, the mean age of ocular SC was found to be 69.19 
and extraocular SC was 67.46 which was also younger 
than other previously published studies based of other eth-
nic populations. This study also revealed a slight female 
predilection. Second, as SC is a rare tumor with a preva-
lence of 1 per 1,000,000, the total number of subjects and 
small differences may not be large enough to effectively 
power a statistically significant comparison. However, 
while further studies with larger number of subjects and 
multivariate analysis are needed, we believe our study is 
still meaningful and contributes significantly as there are 
Clinical Analysis of Sebaceous Neoplasms
Vol. 31, No. 1, 2019 19
Table 3. Comparison of clinical features regarding visceral 
malignancies between patients with sebaceous carcinoma and 
benign sebaceous neoplasm
Factors
Sebaceous 
carcinoma
(n=8)
Benign sebaceous
neoplasms
(n=6)
Age at diagnosis of 
sebaceous neoplasms (yr)
68.1±10.9 53.7±4.8
Gender 
   Male 4 (50.0) 4 (66.7)
   Female 4 (50.0) 2 (33.3)
Number of visceral 
malignancies 
   1 8 (100.0) 3 (50.0)
   2 0 (0.0) 2 (33.3)
   3 0 (0.0) 1 (16.7)
Age at onset of sebaceous 
neoplasms (yr)
66.4±12.1 49.3+13.5
Age at diagnosis of visceral 
malignancies (yr)
63.9±10.3 47.5±5.7
Values are presented as mean±standard deviation or number (%).
Table 4. Type of visceral malignancies associated in sebaceous 
neoplasm patients
Factors
Sebaceous 
carcinoma
(n=8)
Benign 
sebaceous 
neoplasms
(n=10)
Location of visceral 
malignancies 
   GI tract 5 (62.5) 4 (40.0)
     Stomach 2 (25.0) 0 (0.0)
     Colon 2 (25.0) 3 (30.0)
     Rectus 1 (12.5) 1 (10.0)
   Bile duct 0 (0.0) 1 (10.0)
   Thyroid 1 (12.5) 1 (10.0)
   Breast 1 (12.5) 1 (10.0)
   Ureter 0 (0.0) 1 (10.0)
   Prostate 1 (12.5) 1 (10.0)
   Uterus 0 (0.0) 1 (10.0)
Histologic type of visceral 
malignancies 
   Adenocarcinoma 7 (87.5) 6 (60.0)
   Not described 1 (12.5) 4 (40.0)
Values are presented as number (%). GI: gastrointestinal.
not enough previously published statistical data regarding 
SC in Korean patients.
There is little currently known fact regarding BSN, with in-
sufficient demographic data concerning BSN separatedly 
from SC. In our study, the mean age at diagnosis of BSN 
was 58.4 years and there were no gender predilections. 
The most common location of the tumors was the head 
and neck (96.6%), but only 3 cases (10.3%) occurred in 
the ocular area. Overall, we found no significant differ-
ences between the SC group and the BSN group except 
for the location of the tumors.
While the standard treatment for SC is WLE, recently, 
MMS has emerged as an adequate alternative treatment. 
Considering that location of SC is most frequently in cos-
metically sensitive areas such as the eyelids and face, 
MMS would be advantageous because of its superior tu-
mor margin control and preservation of normal skin. 
Furthermore, there are studies reporting that MMS has a 
lower local recurrence rate than WLE5-7. We also consider 
WLE and MMS as first line treatments in our medical cen-
ters, and therefore in our study, surgical excision was the 
first line treatment except for one patient who was unable 
to undergo surgery. Among the 44 patients who were 
treated with WLE, only one patient showed local recurrence. 
There was no local recurrence in patients (n=6) who were 
treated with MMS.
MTS is a rare autosomal-dominant disorder characterized 
by the association of sebaceous gland tumors or other skin 
tumors with one or multiple visceral malignancies. The 
most commonly associated skin neoplasm is sebaceous 
adenoma with a frequency of 68%, followed by SC and 
sebaceoma8. The most commonly associated visceral ma-
lignancy is colorectal adenocarcinoma. The diagnosis of 
MTS can be confirmed by immunohistochemistry on le-
sions which shows loss of staining for MMR gene products 
with high sensitivity8.
However, detailed clinical data is sparse with few reports 
including the MTS portion of all patients with sebaceous 
neoplasms. Such information would be valuable for clini-
cians in guiding decisions on whether further evaluation 
for MTS should be required in patients with sebaceous 
neoplasm.
In our study, 14 patients (17.5%) were found to have asso-
ciated visceral malignancies: 8 patients (15.7%) in the SC 
group and 6 patients (20.7%) in the BSN group. The pro-
portion of patients associated with visceral malignancies is 
not statistically significant but is greater in the BSN group 
than in the SC group. Interestingly, SC group was also 
highly associated with visceral malignancy despite the 
lower incidence of SC associated with MTS compared 
with BSN8. Among these patients, 3 patients in the BSN 
group (50.0%) had multiple visceral malignancies. Among 
the 18 visceral malignancies noted, 50% were of GI tract 
origin. According to the Korean National Cancer Center, 
the total cancer prevalence rate was 2.9%, with 0.6% and 
0.5% prevalence rates in gastric cancers and colorectal 
cancers, respectively9. Compared to this data, the patients 
in our study showed meaningfully high incidence rates of 
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visceral malignancies, especially for GI tract cancers. 
However, patients with visceral malignancy would have 
had regular follow-up on outpatient clinic, and those with 
skin lesions would have been referred to the department 
of dermatology. This could be one of the reasons for a 
higher incidence of visceral malignancy in patients with 
sebaceous neoplasm. Additionally, in the BSN group, the 
mean age at diagnosis of visceral malignancy was 47.5 
years; for the colorectal cancers, the mean age was 45.8 
years. According to the American Cancer Society, color-
ectal cancer is commonly diagnosed after the age of 50 in 
the majority of people, with a similar tendency noted in 
Asian ethnic groups10. When we compare these data, we 
note that the patients in our study developed visceral ma-
lignancies at a much younger age. We also checked the 
order of the incidence of sebaceous neoplasms and viscer-
al malignancies in 14 patients. Although a distinct rela-
tionship was not found, the diagnosis of sebaceous neo-
plasms preceded that of visceral malignancy by 4.2 and 
6.4 years in average in SC and BSN, respectively. In addi-
tion, among the 14 patients, 2 patients with SC had sub-
sequently discovered visceral malignancy during the proc-
ess of work-up for surgery of SC. These results suggest that 
screening for visceral malignancy, especially for the GI 
tract cancers, may be beneficial for patients with seba-
ceous neoplasms. Based on our results, we cautiously rec-
ommend immunohistochemistry for MMR gene prod-
ucts8,11, and additionally, esophagogastroduodenoscopy 
or colonoscopy could be recommended for the patients 
with sebaceous neoplasms12. Considering that sebaceous 
neoplasms are visible lesions which can be easily diag-
nosed with skin biopsy, it would be efficient if this process 
contribute to finding visceral malignancies.
This study has several limitations. First, it was a retro-
spective study with inherent limitations. Second, its study 
population was limited to Korean patients in a tertiary uni-
versity hospital setting. Third, the number of subjects is 
small and may not effectively power statistical analysis for 
significance. Nevertheless, the strengths of this study are 
that it provides information regarding the clinical charac-
teristics of previously little-known sebaceous neoplasms 
and associated visceral malignancies. In particular, this 
study suggests the necessity of screening for visceral ma-
lignancy, especially of the GI tract, in patients with seba-
ceous neoplasms.
Although further studies with a big sample sizes and addi-
tional studies about the efficacy of the screening for the 
visceral malignancies would be needed, we expect this 
study to contribute to comprehending and working-up of 
sebaceous neoplasms.
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